Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: Evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 10, 2007, Pages 3562-3567

  Boyne, Melissa E ^a   Sullivan, Todd J ^b   AmEnde, Christopher W ^b   Lu, Hao ^b   Gruppo, Veronica ^a   Heaslip, Darragh ^a   Amin, Anita G ^a   Chatterjee, Delphi ^a   Lenaerts, Anne ^a   Tonge, Peter J ^b   Slayden, Richard A ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENYL ETHER DERIVATIVE; FATTY ACID; ISONIAZID; OXIDOREDUCTASE; PROTEIN INHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG TOLERABILITY; ENZYME INHIBITION; FATTY ACID SYNTHESIS; FEMALE; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BIOLOGICAL AVAILABILITY; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; DNA FINGERPRINTING; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; FATTY ACIDS; FEMALE; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PHAGOCYTOSIS; PHENYL ETHERS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TRICLOSAN; VERO CELLS;

EID: 34948861094     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00383-07     Document Type: Article

References (20)

1. Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, K. S. Um, T. Wilson, D. Collins, G. D. Lisle, and W. R. Jacobs, Jr. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230.
2. Barry, C. E., III, R. E. Lee, K. Mdluli, A. E. Sampson, B. G. Schroeder, R. A. Slayden, and Y. Yuan. 1998. Mycolic acids: structure, biosynthesis and physiological functions. Prog. Lipid Res. 37:143-179.
3. Barry, C. E., III, R. A. Slayden, A. E. Sampson, and R. E. Lee. 2000. Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem. Pharmacol. 59:221-231.
4. Basso, L. A., R. Zheng, J. M. Musser, W. R. Jacobs, Jr., and J. S. Blanchard. 1998. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 178:769-775.
5. Belisle, J. T., V. D. Vissa, T. Sievert, K. Takayama, P. J. Brennan, and G. S. Besra. 1997. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276:1420-1422.
6. Boshoff, H. I., T. G. Myers, B. R. Copp, M. R. McNeil, M. A. Wilson, and C. E. Barry III. 2004. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279:40174-40184.
7. Colangeli, R., D. Helb, S. Sridharan, J. Sun, M. Varma-Basil, M. H. Hazbon, R. Harbacheuski, N. J. Megjugorac, W. R. Jacobs, Jr., A. Holzenburg, J. C. Sacchettini, and D. Alland. 2005. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol. Microbiol. 55:1829-1840.
8. Gruppo, V., C. M. Johnson, K. S. Marietta, H. Scherman, E. E. Zink, D. C. Crick, L. B. Adams, I. M. Orme, and A. J. Lenaerts. 2006. Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50:1245-1250.
9. Heym, B., P. M. Alzari, N. Honore, and S. T. Cole. 1995. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 15:235-245.
10. Kremer, L., J. D. Douglas, A. R. Baulard, C. Morehouse, M. R. Guy, D. Alland, L. G. Dover, J. H. Lakey, W. R. Jacobs, Jr., P. J. Brennan, D. E. Minnikin, and G. S. Besra. 2000. Thiolactomycin and related-analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem. 275:16857-16864.
11. Li, X. Z., L. Zhang, and H. Nikaido. 2004. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48:2415-2423.
12. Mdluli, K., R. A. Slayden, Y. Zhu, S. Ramaswamy, X. Pan, D. Mead, D. D. Crane, J. M. Musser, and C. E. Barry III. 1998. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 280:1607-1610.
13. Quemard, A., J. C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, J. William, R. Jacobs, and J. S. Blanchard. 1995. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34:8235-8241.
14. Rouse, D. A., Z. Li, G.-H. Bai, and S. L. Morris. 1995. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:2472-2477.
15. Slayden, R. A., and C. E. Barry III. 2000. The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect. 2:659-669.
16. Slayden, R. A., and C. E. Barry III. 2002. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis (Edinburgh) 82:149-160.
17. Slayden, R. A., D. L. Knudson, and J. T. Belisle. 2006. Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis. Microbiology 152:1789-1797.
18. Slayden, R. A., R. E. Lee, J. W. Armour, A. M. Cooper, I. M. Orme, P. J. Brennan, and G. S. Besra. 1996. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob. Agents Chemother. 40:2813-2819.
19. Slayden, R. A., R. E. Lee, and C. E. Barry III. 2000. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol. 38:514-525.
20. Sullivan, T. J., J. J. Truglio, M. E. Boyne, P. Novichenok, X. Zhang, C. F. Stratton, H.-J. Li, T. Kaur, A. Amin, F. Johnson, R. A. Slayden, C. Kisker, and P. J. Tonge. 2006. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol. 1: 43-53.